肠道微生物群在精神疾病中的作用:最新发现。

IF 4.9 2区 医学 Q1 PSYCHIATRY
Current Opinion in Psychiatry Pub Date : 2025-09-01 Epub Date: 2025-06-12 DOI:10.1097/YCO.0000000000001019
Ivona Šimunović Filipčić, Ivana Kolčić, Vladimir Grošić, Igor Filipčić
{"title":"肠道微生物群在精神疾病中的作用:最新发现。","authors":"Ivona Šimunović Filipčić, Ivana Kolčić, Vladimir Grošić, Igor Filipčić","doi":"10.1097/YCO.0000000000001019","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Gut microbiota and its alterations have been increasingly implicated in the pathophysiology of major psychiatric disorders via the microbiota-gut-brain axis. This narrative review aims to highlight current findings from recent systematic reviews and meta-analyses (published between September 2023 and March 2025), addressing the role of gut microbiota in major depressive disorder (MDD) and schizophrenia, with particular attention to the effects of psychotropic medications and microbiota-targeted interventions.</p><p><strong>Recent findings: </strong>In MDD, consistent changes in gut microbiota composition, such as depletion of Faecalibacterium and enrichment of Bifidobacterium, have been reported, although alpha diversity findings remain inconsistent. Antidepressants may modulate microbiota in both humans and animal models, while probiotic and synbiotic interventions yield modest reductions in depressive symptoms and inflammatory markers. In schizophrenia, observational studies showed stable alpha diversity, but altered beta diversity, with taxa like Bifidobacterium , Lactobacillus , and Roseburia linked to symptom severity, cognition, and antipsychotic exposure. Interventional studies, though limited, suggest small-to-moderate clinical improvements with probiotic supplementation, and emerging evidence supports potential benefits for both cognition and reducing metabolic side effects of psychotropic medications.</p><p><strong>Summary: </strong>Across depressive and psychotic disorders, growing evidence supports a multifaceted and indispensable role of gut microbiota in clinical symptomatology, treatment response, and cognition of patients. However, substantial variability of methodological frame, limited sample sizes, lack of mechanistic precision, and heterogeneity between published studies result in unequivocal conclusions on the exact effect of microbiota on mental health in general, and on major psychiatric disorders. While microbiota-targeted therapies remain adjunctive and exploratory, recent findings reinforce them as a promising target for more successful treatment of mental health disorders in the near future. In order to reach that goal, we need more rigorous, longitudinal, and integrative studies to guide the clinical implementation.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":" ","pages":"327-333"},"PeriodicalIF":4.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of gut microbiota in psychiatric disorders: current findings.\",\"authors\":\"Ivona Šimunović Filipčić, Ivana Kolčić, Vladimir Grošić, Igor Filipčić\",\"doi\":\"10.1097/YCO.0000000000001019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>Gut microbiota and its alterations have been increasingly implicated in the pathophysiology of major psychiatric disorders via the microbiota-gut-brain axis. This narrative review aims to highlight current findings from recent systematic reviews and meta-analyses (published between September 2023 and March 2025), addressing the role of gut microbiota in major depressive disorder (MDD) and schizophrenia, with particular attention to the effects of psychotropic medications and microbiota-targeted interventions.</p><p><strong>Recent findings: </strong>In MDD, consistent changes in gut microbiota composition, such as depletion of Faecalibacterium and enrichment of Bifidobacterium, have been reported, although alpha diversity findings remain inconsistent. Antidepressants may modulate microbiota in both humans and animal models, while probiotic and synbiotic interventions yield modest reductions in depressive symptoms and inflammatory markers. In schizophrenia, observational studies showed stable alpha diversity, but altered beta diversity, with taxa like Bifidobacterium , Lactobacillus , and Roseburia linked to symptom severity, cognition, and antipsychotic exposure. Interventional studies, though limited, suggest small-to-moderate clinical improvements with probiotic supplementation, and emerging evidence supports potential benefits for both cognition and reducing metabolic side effects of psychotropic medications.</p><p><strong>Summary: </strong>Across depressive and psychotic disorders, growing evidence supports a multifaceted and indispensable role of gut microbiota in clinical symptomatology, treatment response, and cognition of patients. However, substantial variability of methodological frame, limited sample sizes, lack of mechanistic precision, and heterogeneity between published studies result in unequivocal conclusions on the exact effect of microbiota on mental health in general, and on major psychiatric disorders. While microbiota-targeted therapies remain adjunctive and exploratory, recent findings reinforce them as a promising target for more successful treatment of mental health disorders in the near future. In order to reach that goal, we need more rigorous, longitudinal, and integrative studies to guide the clinical implementation.</p>\",\"PeriodicalId\":11022,\"journal\":{\"name\":\"Current Opinion in Psychiatry\",\"volume\":\" \",\"pages\":\"327-333\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/YCO.0000000000001019\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YCO.0000000000001019","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

综述目的:肠道微生物群及其改变通过微生物群-肠-脑轴与主要精神疾病的病理生理关系越来越密切。本综述旨在强调近期系统综述和荟萃分析(发表于2023年9月至2025年3月之间)的最新发现,探讨肠道微生物群在重度抑郁症(MDD)和精神分裂症中的作用,特别关注精神药物和微生物群靶向干预的影响。最近的发现:在MDD中,尽管α多样性的发现仍然不一致,但肠道微生物群组成的一致变化,如Faecalibacterium的减少和双歧杆菌的富集,已被报道。抗抑郁药可以调节人类和动物模型中的微生物群,而益生菌和合成菌干预可以适度减少抑郁症状和炎症标志物。在精神分裂症中,观察性研究显示稳定的α多样性,但改变了β多样性,类群如双歧杆菌、乳酸杆菌和Roseburia与症状严重程度、认知和抗精神病药物暴露有关。干预性研究虽然有限,但表明补充益生菌有小到中等程度的临床改善,并且新出现的证据支持对认知和减少精神药物代谢副作用的潜在益处。总结:在抑郁症和精神障碍中,越来越多的证据支持肠道微生物群在临床症状、治疗反应和患者认知方面具有多方面和不可或缺的作用。然而,方法框架的巨大差异、有限的样本量、缺乏机制精度以及已发表研究之间的异质性导致了微生物群对一般心理健康和主要精神疾病的确切影响的明确结论。虽然微生物群靶向治疗仍然是辅助的和探索性的,但最近的研究结果加强了它们作为在不久的将来更成功治疗精神健康障碍的有希望的目标。为了达到这一目标,我们需要更严格、纵向和综合的研究来指导临床实施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The role of gut microbiota in psychiatric disorders: current findings.

Purpose of review: Gut microbiota and its alterations have been increasingly implicated in the pathophysiology of major psychiatric disorders via the microbiota-gut-brain axis. This narrative review aims to highlight current findings from recent systematic reviews and meta-analyses (published between September 2023 and March 2025), addressing the role of gut microbiota in major depressive disorder (MDD) and schizophrenia, with particular attention to the effects of psychotropic medications and microbiota-targeted interventions.

Recent findings: In MDD, consistent changes in gut microbiota composition, such as depletion of Faecalibacterium and enrichment of Bifidobacterium, have been reported, although alpha diversity findings remain inconsistent. Antidepressants may modulate microbiota in both humans and animal models, while probiotic and synbiotic interventions yield modest reductions in depressive symptoms and inflammatory markers. In schizophrenia, observational studies showed stable alpha diversity, but altered beta diversity, with taxa like Bifidobacterium , Lactobacillus , and Roseburia linked to symptom severity, cognition, and antipsychotic exposure. Interventional studies, though limited, suggest small-to-moderate clinical improvements with probiotic supplementation, and emerging evidence supports potential benefits for both cognition and reducing metabolic side effects of psychotropic medications.

Summary: Across depressive and psychotic disorders, growing evidence supports a multifaceted and indispensable role of gut microbiota in clinical symptomatology, treatment response, and cognition of patients. However, substantial variability of methodological frame, limited sample sizes, lack of mechanistic precision, and heterogeneity between published studies result in unequivocal conclusions on the exact effect of microbiota on mental health in general, and on major psychiatric disorders. While microbiota-targeted therapies remain adjunctive and exploratory, recent findings reinforce them as a promising target for more successful treatment of mental health disorders in the near future. In order to reach that goal, we need more rigorous, longitudinal, and integrative studies to guide the clinical implementation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Opinion in Psychiatry
Current Opinion in Psychiatry 医学-精神病学
CiteScore
12.20
自引率
1.40%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Current Opinion in Psychiatry is an easy-to-digest bimonthly journal covering the most interesting and important advances in the field of psychiatry. Eight sections on mental health disorders including schizophrenia, neurodevelopmental disorders and eating disorders, are presented alongside five area-specific sections, offering an expert evaluation on the most exciting developments in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信